Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Vacca

Showing results (271-280 of 347) with videos related to

Pageof 35
Sort By:
Leukemia & Lymphoma|November 2, 2020
TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killingAntonia Reale, Tiffany Khong, Sridurga Mithraprabhu, et al.
Diagnostics (Basel, Switzerland)|August 26, 2022
Dermatopathology of Malignant Melanoma in the Era of Artificial Intelligence: A Single Institutional ExperienceGerardo Cazzato, Alessandro Massaro, Anna Colagrande, et al.
Cancer Research|January 7, 2006
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cellsAldo Maria Roccaro, Teru Hideshima, Noopur Raje, et al.
Surgery|June 3, 2020
Effect of thyroidectomy on circulating angiogenic cytokines in papillary thyroid carcinoma and benign goiter: Potential for new biomarkers?Roberto Ria, Francesco Prete, Assunta Melaccio, et al.
Oncoimmunology|December 15, 2018
Bone marrow endothelial cells sustain a tumor-specific CD8<sup>+</sup> T cell subset with suppressive function in myeloma patientsPatrizia Leone, Giuseppe Di Lernia, Antonio Giovanni Solimando, et al.
Blood|June 6, 2008
Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinibAddolorata Maria Luce Coluccia, Teresa Cirulli, Paola Neri, et al.
Experimental Cell Research|July 25, 2016
Corrigendum to "Isolation and characterization of neural stem cells from dystrophic mdx mouse" [Exp. Cell Res. 343(2016)190-207]Tiziana Annese, Patrizia Corsi, Simona Ruggieri, et al.
Oncoimmunology|July 9, 2015
Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myelomaArianna Calcinotto, Maurilio Ponzoni, Roberto Ria, et al.
Cancers|August 7, 2021
MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma DiseaseVanessa Desantis, Antonio Giovanni Solimando, Ilaria Saltarella, et al.
Internal and Emergency Medicine|January 28, 2025
Genomic profiling at a single center cracks the code in inborn errors of immunityAlessandro Andriano, Vanessa Desantis, Carolina Marasco, et al.
Pageof 35

Showing results (271-280 of 347) with videos related to

Sort By:
Pageof 35
Leukemia & Lymphoma|November 2, 2020
TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killingAntonia Reale, Tiffany Khong, Sridurga Mithraprabhu, et al.
Diagnostics (Basel, Switzerland)|August 26, 2022
Dermatopathology of Malignant Melanoma in the Era of Artificial Intelligence: A Single Institutional ExperienceGerardo Cazzato, Alessandro Massaro, Anna Colagrande, et al.
Cancer Research|January 7, 2006
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cellsAldo Maria Roccaro, Teru Hideshima, Noopur Raje, et al.
Surgery|June 3, 2020
Effect of thyroidectomy on circulating angiogenic cytokines in papillary thyroid carcinoma and benign goiter: Potential for new biomarkers?Roberto Ria, Francesco Prete, Assunta Melaccio, et al.
Oncoimmunology|December 15, 2018
Bone marrow endothelial cells sustain a tumor-specific CD8<sup>+</sup> T cell subset with suppressive function in myeloma patientsPatrizia Leone, Giuseppe Di Lernia, Antonio Giovanni Solimando, et al.
Blood|June 6, 2008
Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinibAddolorata Maria Luce Coluccia, Teresa Cirulli, Paola Neri, et al.
Experimental Cell Research|July 25, 2016
Corrigendum to "Isolation and characterization of neural stem cells from dystrophic mdx mouse" [Exp. Cell Res. 343(2016)190-207]Tiziana Annese, Patrizia Corsi, Simona Ruggieri, et al.
Oncoimmunology|July 9, 2015
Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myelomaArianna Calcinotto, Maurilio Ponzoni, Roberto Ria, et al.
Cancers|August 7, 2021
MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma DiseaseVanessa Desantis, Antonio Giovanni Solimando, Ilaria Saltarella, et al.
Internal and Emergency Medicine|January 28, 2025
Genomic profiling at a single center cracks the code in inborn errors of immunityAlessandro Andriano, Vanessa Desantis, Carolina Marasco, et al.
Pageof 35